KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $1.6 million.

  • Travere Therapeutics' Other Operating Expenses fell 252.15% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 8620.86%. This contributed to the annual value of $72.9 million for FY2024, which is 53710.92% up from last year.
  • As of Q3 2025, Travere Therapeutics' Other Operating Expenses stood at $1.6 million, which was down 252.15% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Other Operating Expenses peaked at $66.7 million during Q1 2024, and registered a low of -$25.0 million during Q4 2021.
  • Its 5-year average for Other Operating Expenses is $4.4 million, with a median of $1.6 million in 2024.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 195362.32% in 2021, then tumbled by 27405.06% in 2022.
  • Quarter analysis of 5 years shows Travere Therapeutics' Other Operating Expenses stood at -$25.0 million in 2021, then skyrocketed by 103.47% to $868000.0 in 2022, then soared by 425.81% to $4.6 million in 2023, then crashed by 44.06% to $2.6 million in 2024, then tumbled by 37.92% to $1.6 million in 2025.
  • Its Other Operating Expenses stands at $1.6 million for Q3 2025, versus $1.5 million for Q2 2025 and $4.7 million for Q1 2025.